Literature DB >> 11849766

14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease.

Raquel Sánchez-Valle1, Albert Saiz, Francesc Graus.   

Abstract

A positive 14-3-3 assay is a criterion for probable Creutzfeldt-Jakob disease (CJD). Cerebrospinal fluid (CSF) 14-3-3 is usually detected by immunoblot using an antibody that recognizes all of the 14-3-3 isoforms. In a few cases, the antibody recognizes an inferior band and this pattern is associated with false positive results. We analyzed 43 CSF (26 CJD, 17 controls) samples using antibodies against specific isoforms (beta, epsilon, gamma, tau, xi) and compared the results with those obtained with the standard antibody. The anti-gamma and anti-beta antibody achieved similar results but the presence of atypical patterns made the standard antibody more accurate for the CJD diagnosis. To study the nature of the inferior band, CSF samples were probed with antibodies against light chain immunoglobulins, and immunoblots of human IgG with the standard antibody. The experiments suggested a cross-reaction of the anti-14-3-3 antibody with light chain immunoglobulins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849766     DOI: 10.1016/s0304-3940(02)00045-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy.

Authors:  T Vander; C Hallevy; I Alsaed; S Valdman; G Ifergane; I Wirguin
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

2.  Detection of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated Capillary Western Assay.

Authors:  A Fourier; A Dorey; A Perret-Liaudet; I Quadrio
Journal:  Mol Neurobiol       Date:  2017-05-16       Impact factor: 5.590

Review 3.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

4.  Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease.

Authors:  Maria Carmela Tartaglia; David Y Johnson; Julie Ngoc Thai; Tatiana Cattaruzza; Katherine Wong; Paul Garcia; Stephen J Dearmond; Bruce L Miller; Michael D Geschwind
Journal:  Can J Neurol Sci       Date:  2012-05       Impact factor: 2.104

5.  [Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia].

Authors:  J Hort; M Valis; G Waberzinek; R Taláb; L Glossová; M Bojar; M Vyhnálek; D Skoda; J Masopust; P Stourac
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

6.  Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory.

Authors:  Jae Wook Hyeon; Su Yeon Kim; Jeongmin Lee; Jun Sun Park; Kyu Jam Hwang; Sol Moe Lee; SeongSoo A An; Myung Koo Lee; Young Ran Ju
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.